
Statins Related to Diabetes Progression for Obese Patients
Statin therapy may be elevating risk of type 2 diabetes in high-risk adults.
Statins or HMG-CoA reductase inhibitors provide several cardiovascular benefits in addition to lowering cholesterol. This could lead individuals to believe that statins may potentially aid in reducing diabetes risk. However, in numerous cardiovascular disease (CV) prevention studies, it has been consistently found that diabetes risk is increased with statin therapy. Because diabetes is not usually a direct measure in these CV disease studies, participants are often low-risk.
The following study aimed to evaluate the effect of statin therapy on diabetes patients who are considered high-risk. Population data was analyzed from a 3-year study called the Diabetes Prevention Program (DPP), and an extension of this study called the DPP Outcomes Study (DPPOS). The DPP is a randomized, controlled trial that studied the effect of lifestyle changes, metformin use, and placebo on high-risk patients with obesity or overweight. There were 3,234 participants randomized to receive 1 of the 3 interventions. Participants were included if they were older than 25 years of age, had obesity or were overweight, had high fasting blood sugar levels, and had impaired glucose tolerance. Following the DPP, participants were given the option to join the DPPOS extension study.
In both the DPP and DPPOS, use of statins and other medications was obtained through patient self-report at baseline and twice yearly at follow-up visits. Statin therapy along with hypertensive therapy was determined by the participants primary physi
Continue
reading